Invasion of tumorigenic HT1080 cells is impeded by blocking or downregulating the 37-kDa/67-kDa laminin receptor

被引:54
|
作者
Zuber, Chantal [1 ]
Knackmaass, Stefan [2 ]
Zemora, Georgeta [1 ]
Reusch, Uwe [2 ]
Vlasova, Ekaterina [1 ]
Diehl, Daniela [3 ]
Mick, Vera [2 ]
Hoffman, Karen [2 ]
Nikles, Daphne [1 ]
Froehlich, Thomas [4 ]
Arnold, Georg J. [4 ]
Brenig, Bertram [5 ]
Wolf, Eckhard [3 ]
Lahm, Harald [3 ]
Little, Melvyn [2 ]
Weiss, Stefan [1 ]
机构
[1] LMU Munchen, Mol Biol Lab, Genzentrum, Inst Biochem, D-81377 Munich, Germany
[2] Affimed Therapeut AG, D-69120 Heidelberg, Germany
[3] LMU Munchen, Inst Mol Tierzucht & Biotechnol, Genzentrum, D-81377 Munich, Germany
[4] LMU Munchen, Lab Funct Genome Analysis, D-81377 Munich, Germany
[5] Univ Gottingen, Tieraztl Inst, D-37077 Gottingen, Germany
关键词
laminin receptor; prion; cancer; metastasis; therapy;
D O I
10.1016/j.jmb.2008.02.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The 37-kDa/67-kDa laminin receptor precursor/laminin receptor (LRP/LR) acting as a receptor for prions and viruses is overexpressed in various cancer cell lines, and their metastatic potential correlates with LRP/LR levels. We analyzed the tumorigenic fibrosarcoma cell line HT1080 regarding 37-kDa/67-kDa LRP/LR levels and its invasive potential. Compared to the less invasive embryonic fibroblast cell line NIH3T3, the tumorigenic HT1080 cells display approximately 1.6-fold higher cell-surface levels of LRP/LR. We show that anti-LRP/LR tools interfere with the invasive potential of HT1080 cells. Anti-LRP/LR single-chain variable fragment antibody (scFv) iS18 generated by chain shuffling from parental scFv S18 and its full-length version immunoglobulin G1-iS18 reduced the invasive potential of HT1080 cells significantly by 37% and 38%, respectively. HT1080 cells transfected with lentiviral plasmids expressing small interfering RNAs directed against LRP mRNA showed reduced LRP levels by approximately 44%, concomitant with a significant decrease in the invasive potential by approximately 37%. The polysulfated glycans HM2602 and pentosan polysulfate (SP-54), both capable of blocking LRP/LR, reduced the invasive potential by 20% and 35%, respectively. Adhesion of HT1080 cells to laminin-1 was significantly impeded by scFv iS18 and immunoglobulin G1-iS18 by 60% and 68%, respectively, and by SP-54 and HM2602 by 80%, suggesting that the reduced invasive capacity achieved by these tools is due to the perturbation of the LRP/LR-laminin interaction on the cell surface. Our in vitro data suggest that reagents directed against LRP/LR or LRP mRNA such as antibodies, polysulfated glycans, or small interfering RNAs, previously shown to encompass an anti-prion activity by blocking or downregulating the prion receptor LRP/LR, might also be potential cancer therapeutics blocking metastasis by interfering with the LRP/LR-laminin interaction in neoplastic tissues. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:530 / 539
页数:10
相关论文
共 47 条
  • [21] The 67-kDa laminin receptor originated from a ribosomal protein that acquired a dual function during evolution
    Ardini, E
    Pesole, G
    Tagliabue, E
    Magnifico, A
    Castronovo, V
    Sobel, ME
    Colnaghi, MI
    Ménard, S
    MOLECULAR BIOLOGY AND EVOLUTION, 1998, 15 (08) : 1017 - 1025
  • [22] Novel patented therapeutic approaches targeting the 37/67 kDa laminin receptor for treatment of cancer and Alzheimer's disease
    Jovanovic, Katarina
    Chetty, Carryn J.
    Khumalo, Thandokuhle
    Dias, Bianca Da Costa
    Ferreira, Eloise
    Malindisa, Sibusiso T.
    Caveney, Robert
    Letsolo, Boitelo T.
    Weiss, Stefan F. T.
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2015, 25 (05) : 567 - 582
  • [23] 67-kDa laminin receptor mediates oolonghomobisflavan B-induced cell growth inhibition in melanoma
    Bae, Jaehoon
    Kumazoe, Motofumi
    Lee, Kwan-Woo
    Fujimura, Yoshinori
    Tachibana, Hirofumi
    PHYTOMEDICINE, 2023, 118
  • [24] Single chain Fv antibodies directed against the 37 kDa/67 kDa laminin receptor as therapeutic tools in prion diseases
    Zuber, Chantal
    Knackmuss, Stefan
    Rey, Clemence
    Reusch, Uwe
    Roettgen, Peter
    Froehlich, Thomas
    Arnold, Georg J.
    Pace, Claudia
    Mitteregger, Gerda
    Kretzschmar, Hans A.
    Little, Melvyn
    Weiss, Stefan
    MOLECULAR IMMUNOLOGY, 2008, 45 (01) : 144 - 151
  • [25] The Role of MAPK-ERK Pathway in 67-kDa Laminin Receptor-Induced FasL Expression in Human Cholangiocarcinoma Cells
    Shi-Gang Duan
    Long Cheng
    Da-Jiang Li
    Jin Zhu
    Yan Xiong
    Xiao-Wu Li
    Shu-Guang Wang
    Digestive Diseases and Sciences, 2010, 55 : 2844 - 2852
  • [26] Diminution of 37-kDa laminin binding protein expression reduces tumour formation of murine lung cancer cells
    K Satoh
    K Narumi
    T Abe
    T Sakai
    T Kikuchi
    M Tanaka
    T Shimo-Oka
    M Uchida
    F Tezuka
    M Isemura
    T Nukiwa
    British Journal of Cancer, 1999, 80 : 1115 - 1122
  • [27] Extraribosomal functions associated with the C terminus of the 37/67 kDa laminin receptor are required for maintaining cell viability
    Scheiman, J.
    Jamieson, K. V.
    Ziello, J.
    Tseng, J-C
    Meruelo, D.
    CELL DEATH & DISEASE, 2010, 1 : e42 - e42
  • [28] Diminution of 37-kDa laminin binding protein expression reduces tumour formation of murine lung cancer cells
    Satoh, K
    Narumi, K
    Abe, T
    Sakai, T
    Kikuchi, T
    Tanaka, M
    Shimo-Oka, T
    Uchida, M
    Tezuka, F
    Isemura, M
    Nukiwa, T
    BRITISH JOURNAL OF CANCER, 1999, 80 (08) : 1115 - 1122
  • [29] Changes in subcellular localization of Lysyl-tRNA synthetase and the 67-kDa laminin receptor in epithelial ovarian cancer metastases
    Lee, Dae Hoon
    Paik, E. Sun
    Cho, Young-Jae
    Lee, Yoo-Young
    Lee, Bada
    Lee, Eui Jin
    Choi, Jung-Joo
    Choi, Chel-Hun
    Lee, Sangmin
    Choi, Jin Woo
    Lee, Jeong-Won
    CANCER BIOMARKERS, 2022, 35 (01) : 99 - 109
  • [30] Inhibition of experimental metastasis of human fibrosarcoma cells by anti-recombinant 37-kDa laminin binding protein antibody
    Narumi, K
    Inoue, A
    Tanaka, H
    Isemura, M
    Shimo-Oka, T
    Abe, T
    Nukiwa, T
    Satoh, K
    JAPANESE JOURNAL OF CANCER RESEARCH, 1999, 90 (04): : 425 - 431